A. D. Beadell Investment Counsel Inc. acquired a new stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 13,385 shares of the company’s stock, valued at approximately $876,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of AZN. Martin Investment Management LLC lifted its position in AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after purchasing an additional 7,615 shares during the last quarter. Integrated Advisors Network LLC increased its stake in AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after acquiring an additional 13,860 shares during the last quarter. Creative Planning lifted its stake in AstraZeneca by 8.0% during the third quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after purchasing an additional 16,692 shares during the last quarter. Soros Fund Management LLC increased its position in shares of AstraZeneca by 8.2% during the 3rd quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock valued at $206,677,000 after purchasing an additional 201,233 shares during the last quarter. Finally, Optas LLC raised its stake in shares of AstraZeneca by 173.5% during the third quarter. Optas LLC now owns 15,570 shares of the company’s stock worth $1,213,000 after acquiring an additional 9,877 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.
AstraZeneca Stock Up 0.9 %
Shares of AZN stock traded up $0.63 during mid-day trading on Friday, reaching $67.21. 2,141,876 shares of the company’s stock traded hands, compared to its average volume of 3,698,457. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The company’s 50-day moving average price is $66.20 and its 200-day moving average price is $75.01. The company has a market cap of $208.39 billion, a P/E ratio of 32.16, a P/E/G ratio of 1.19 and a beta of 0.46.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the company. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $89.75.
Read Our Latest Stock Analysis on AZN
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- Using the MarketBeat Stock Split Calculator
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What is the Hang Seng index?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Short Selling – The Pros and Cons
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.